Regulatory and market access improvements for medtech products were on the agenda at last month's Health Products Regulatory Forum in Singapore. These forward-looking changes are seen by the government and the Health Sciences Authority (HSA) as the medtech sector's contribution to initiatives and aims developed by the Singapore Committee on the Future Economy (CFE).

After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.

Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.